Mycrodose Therapeutics Successfully Delivers Both Macro and Microdose Levels of Psilocin Using Core Drug Delivery Technologies

San Diego, California–(Newsfile Corp. – May 10, 2022) – Mycrodose Therapeutics showed the ability to synthesize and stabilize psilocin in their laboratory for use in their IP-protected drug delivery systems. The company successfully delivered in vitro both macro and microdose levels of psilocin through human skin using their patch and lozenge technologies.

Mycrodose Therapeutics (“Mycrodose”), a leading US pharmaceutical company specializing in the development of advanced drug delivery (ADD) technologies utilizing DEA Schedule I & III drugs and other compounds, announced today their successful in vitro pre-clinical research study showing the ability to synthesize and stabilize psilocin, the active pharmaceutical ingredient (API), in-vitro through human skin using their proprietary transdermal patch and lozenge technology. Mycrodose’s in vitro studies also showed that the company’s technologies were able to deliver both macro and microdose levels of psilocin into circulation.

“With the upgrade to our in vitro penetration test setup, we are now researching transdermal drug delivery beyond the 1-day patch, extending up to one-week delivery,” says Frank Kochinke, Chief Science Officer, Mycrodose Therapeutics. “However, thinking the opposite way, larger doses within a shorter time interval, essentially macrodosing is potentially possible. Our preliminary results suggest that larger doses, such as a standard macrodose, of psilocin can be delivered via our proprietary transdermal and transmucosal technologies. The technological hurdles that remain are to convert the exciting results into a 2-year shelf-life product. To accomplish that we are enhancing our analytical capabilities and implementing stability-indicating assays as well as using upgraded LC/MS equipment to research psilocin’s metabolites and degradation products. These are needed to be prepared for our projected clinical studies evaluating the prototypes for several indications in large mental and general health market segments,” Kochinke continued.

Mycrodose Therapeutics’ preclinical results show that the active compound psilocin, both extracted from psilocybin mushrooms and synthesized at Mycrodose’s laboratory to cGMP standards, can be stabilized before being delivered transdermally and transmucosally, through the company’s controlled and sustained-release drug delivery technology.

“We have successfully synthesized psilocin, developed a psilocin transdermal drug delivery system and performed in vitro permeation studies with our semi-automatic permeation instrument. We utilized human skin for in-vitro studies, which is donated from local surgery centers and dermatomed in-house. It is important to note all of the aforementioned processes were done in-house, at our research facility.” says Bryan Arrayales, Director of R&D, Mycrodose Therapeutics.

With respect to the instability of psilocin, Mycrodose Therapeutics is currently on track to further stabilize psilocin inside its respective drug delivery systems to increase the APIs shelf life. Through rigorous studies, Mycrodose can deliver micro and macro amounts of psilocin giving the company multiple treatment options with respect to patient demand.

The results of the research further show that the company’s ability to control and sustain the delivery of psilocin is possible by increasing or decreasing permeation rates through human skin. The research also showed that a larger dose, a macro dose level, of psilocin can be delivered effectively using the company’s patch and lozenge technology.

Upcoming plans of the company include the synthesis of LSD to be used in the development of an LSD transdermal and sublingual drug delivery system.

About Mycrodose Therapeutics

Mycrodose Therapeutics Inc. is a U.S.-based pharmaceutical company headquartered in San Diego, California specializing in the development of advanced drug delivery systems utilizing DEA Schedule I & III drugs and other compounds to treat cancer related conditions, mental health, and cognitive degenerative diseases. Mycrodose’s state-of-the-art laboratory includes a transdermal department with full in-vitro and analytical capacities that allows for all intellectual property and proprietary data to remain in-house. The company believes that its IP-Protected Sustained Microdosing Technologyâ„¢ is a smarter and safer approach to delivering pharmaceutical compounds to patients of all ages and allows for an expandable and scalable business model.

For more information about Mycrodose Therapeutics, please contact:

Patrick Eckstrom
Chief Operating Officer
Mycrodose Therapeutics
Email: [email protected]
Phone: 1-619-494-1367
Website: www.MycrodoseThera.com

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/123410

error: Content is protected !!